The FDA's April 2026 proposal would end large-scale compounding of semaglutide and tirzepatide. Individual-patient compounding isn't affected, but the supply picture is about to shrink.

A trial in adults with HIV found semaglutide slowed one measure of biological aging by 9% versus placebo. Researchers call it an early signal, not evidence the drug reverses aging.